<div id="readability-page-1"><div><p>(MT Newswires) -- China Meheco Group's (SHA:600056) unit, Tianfang Pharmaceutical, received approval from the Chinese drug administrator for its drug supplementary application for lincomycin hydrochloride injection after the drug passed regulatory evaluation, according to a Shanghai bourse filing on Wednesday.</p><p> The drug, which is mainly used for the treatment of severe infections caused by susceptible strains such as streptococci, pneumococci, and staphylococci, was tested for its consistency in quality and efficiency.</p><p>The Chinese drugmaker's shares dropped less than 2% during the afternoon trade.</p></div></div>

中國醫藥

<p>（MT Newswires）-- 中國醫藥（SHA:600056）旗下的天方藥業在週三的上海證券交易所公告中表示，已獲得中國藥品監管部門對其林可黴素鹽酸鹽注射液的藥品補充申請的批准，該藥品在監管評估中通過。該藥物主要用於治療由易感菌株（如鏈球菌、肺炎球菌和金黃色葡萄球菌）引起的嚴重感染，經過了質量和效率的一致性測試。該中國製藥公司的股票在下午交易中下跌了不到 2%</p>

中國醫藥的子公司在通過評估後，獲得了林可黴素鹽酸注射液補充申請的批准